PriceTargets.com logo

OTCMKTS:SONVY - Sonova Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$49.66 As of 03/3/2021 01:00 AM ET
▼ -2.36 (-4.54%)
1 month | 3 months | 12 months
Get New Sonova Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SONVY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SONVY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Sonova in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $49.66.
Hold
The current consensus among 9 polled investment analysts is to hold stock in Sonova. This rating has held steady since October 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/9/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/8/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
6/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
9/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/18/2021Exane BNP ParibasUpgradeUnderperform ➝ Outperform
i
2/2/2021UBS GroupReiterated RatingNeutral
i
12/9/2020Morgan StanleyReiterated RatingEqual Weight
i
12/1/2020Jefferies Financial GroupUpgradeHold ➝ Buy
i
11/24/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
11/23/2020Berenberg BankReiterated RatingHold
i
11/17/2020Credit Suisse GroupReiterated RatingOutperform
i
11/17/2020UBS GroupReiterated RatingNeutral
i
11/5/2020Berenberg BankReiterated RatingHold
i
10/8/2020Credit Suisse GroupReiterated RatingOutperform
i
10/8/2020CitigroupInitiated CoverageNeutral
i
9/30/2020JPMorgan Chase & Co.Reiterated RatingNeutral
i
9/29/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
9/29/2020UBS GroupReiterated RatingNeutral
i
9/2/2020UBS GroupReiterated RatingNeutral
i
7/27/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight
i
5/22/2020UBS GroupDowngradeBuy ➝ Neutral
i
5/21/2020JPMorgan Chase & Co.UpgradeNeutral
i
5/20/2020Deutsche Bank AktiengesellschaftReiterated RatingHold
i
5/12/2020Berenberg BankReiterated RatingHold
i
4/17/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
i
4/9/2020Jefferies Financial GroupDowngradeBuy ➝ Hold
i
1/5/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight
i
10/31/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell
i
9/10/2019Jefferies Financial GroupUpgradeHold ➝ Buy
i
1/14/2019UBS GroupUpgradeNeutral ➝ Buy
i
2/6/2017UBS GroupDowngradeNeutral ➝ Sell
i
9/29/2016Credit Suisse GroupReiterated RatingOutperform
i
(Data available from 3/4/2016 forward)
Sonova logo
Sonova Holding AG designs, develops, manufactures, and distributes hearing systems for adults and children with hearing impairment. It operates through two segments, Hearing Instruments and Cochlear Implants segments. It offers wireless communication products, rechargeable hearing aids, and professional audiological care services. The company provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; and professional hearing care services under the AudioNova, Audium, AuditionSanté, Boots Hearingcare, Connect Hearing, Fiebing, Geers, Hansaton, Lapperre, Lindacher, Schoonenberg, Triton, and Vitakustik brands. Sonova Holding AG sells its products through wholesale companies and independent distributors; and provides professional audiological care services through a network of approximately 3,500 stores and clinics. It operates in the Americas, Europe, the Middle East, Africa, and the Asia/Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.
Read More

Today's Range

Now: $49.66
$49.23
$50.15

50 Day Range

MA: $51.33
$48.30
$54.02

52 Week Range

Now: $49.66
$29.41
$54.77

Volume

15,511 shs

Average Volume

17,737 shs

Market Capitalization

$15.99 billion

P/E Ratio

33.33

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Sonova?

The following Wall Street sell-side analysts have issued reports on Sonova in the last twelve months: Berenberg Bank, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Exane BNP Paribas, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for SONVY.

What is the current price target for Sonova?

0 Wall Street analysts have set twelve-month price targets for Sonova in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Sonova in the next year.
View the latest price targets for SONVY.

What is the current consensus analyst rating for Sonova?

Sonova currently has 6 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SONVY, but not buy more shares or sell existing shares.
View the latest ratings for SONVY.

What other companies compete with Sonova?

Other companies that are similar to Sonova include Varian Medical Systems, Masimo, Getinge, LivaNova, CONMED, InMode, Outset Medical, BioLife Solutions, TransMedics Group, AxoGen, Natus Medical, Semler Scientific, ViewRay, Cutera and Stereotaxis.

How do I contact Sonova's investor relations team?

Sonova's physical mailing address is Laubisrutistrasse 28, Stafa V8, 8712. The company's listed phone number is 41-58-928-3333 and its investor relations email address is [email protected] The official website for Sonova is www.sonova.com.